UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in STERIS plc (NYSE:STE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in STERIS plc (NYSE:STE - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 979,480 shares of the medical equipment provider's stock after purchasing an additional 75,877 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.00% of STERIS worth $201,342,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Magnolia Capital Advisors LLC boosted its position in STERIS by 1.9% in the fourth quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider's stock worth $521,000 after purchasing an additional 48 shares during the last quarter. Park Edge Advisors LLC boosted its position in STERIS by 1.1% in the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider's stock worth $958,000 after purchasing an additional 51 shares during the last quarter. Citizens Financial Group Inc. RI boosted its position in STERIS by 5.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 975 shares of the medical equipment provider's stock worth $201,000 after purchasing an additional 54 shares during the last quarter. Opal Wealth Advisors LLC boosted its position in STERIS by 5.7% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider's stock worth $230,000 after purchasing an additional 60 shares during the last quarter. Finally, Sage Private Wealth Group LLC boosted its position in STERIS by 4.1% in the fourth quarter. Sage Private Wealth Group LLC now owns 1,537 shares of the medical equipment provider's stock worth $316,000 after purchasing an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

STERIS Stock Down 1.1%

STE stock opened at $243.61 on Friday. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $23.93 billion, a PE ratio of 51.72 and a beta of 0.96. STERIS plc has a twelve month low of $200.98 and a twelve month high of $252.79. The stock has a 50-day simple moving average of $225.95 and a two-hundred day simple moving average of $220.00.

STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.15. The business had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The company's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.58 EPS. On average, equities analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's payout ratio is presently 36.77%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on STE shares. Morgan Stanley boosted their target price on STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a research note on Monday. Piper Sandler boosted their target price on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research note on Thursday. JMP Securities boosted their target price on STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a research note on Friday, May 16th. Finally, Stephens restated an "overweight" rating and issued a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $264.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.